Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers.
Identifieur interne : 000149 ( Main/Exploration ); précédent : 000148; suivant : 000150Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers.
Auteurs : Andreas E. Kremer [Pays-Bas] ; Christian Rust ; Peter Eichhorn ; Ulrich Beuers ; Stefan HoldenriederSource :
- Expert review of molecular diagnostics [ 1744-8352 ] ; 2009.
Descripteurs français
- KwdFr :
- Apoptose (MeSH), Humains (MeSH), Maladies auto-immunes (diagnostic), Maladies auto-immunes (immunologie), Maladies auto-immunes (sang), Maladies auto-immunes (thérapie), Maladies du foie (diagnostic), Maladies du foie (immunologie), Maladies du foie (sang), Maladies du foie (thérapie), Marqueurs biologiques (sang), Monitorage physiologique (méthodes).
- MESH :
- diagnostic : Maladies auto-immunes, Maladies du foie.
- immunologie : Maladies auto-immunes, Maladies du foie.
- méthodes : Monitorage physiologique.
- sang : Maladies auto-immunes, Maladies du foie, Marqueurs biologiques.
- thérapie : Maladies auto-immunes, Maladies du foie.
- Apoptose, Humains.
English descriptors
- KwdEn :
- Apoptosis (MeSH), Autoimmune Diseases (blood), Autoimmune Diseases (diagnosis), Autoimmune Diseases (immunology), Autoimmune Diseases (therapy), Biomarkers (blood), Humans (MeSH), Liver Diseases (blood), Liver Diseases (diagnosis), Liver Diseases (immunology), Liver Diseases (therapy), Monitoring, Physiologic (methods).
- MESH :
- chemical , blood : Biomarkers.
- blood : Autoimmune Diseases, Liver Diseases.
- diagnosis : Autoimmune Diseases, Liver Diseases.
- immunology : Autoimmune Diseases, Liver Diseases.
- methods : Monitoring, Physiologic.
- therapy : Autoimmune Diseases, Liver Diseases.
- Apoptosis, Humans.
Abstract
Primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis are the three major immune-mediated liver diseases. The etiologies of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis are largely unknown, but seem to be influenced by genetic and environmental factors. Autoantibodies can be found in nearly all patients with primary sclerosing cholangitis and autoimmune hepatitis, and in the vast majority of patients with primary sclerosing cholangitis. In addition, autoimmune hepatitis is associated with high concentrations of serum globulins. Enhanced liver cell death by apoptosis has been described in all of these liver diseases, although the precise mechanisms remain unclear. In general, apoptosis can be initiated via an extrinsic pathway that is triggered by engagement of death receptors on the cell surface, or via an intrinsic pathway that is induced by mitochondrial injury and is influenced by members of the Bcl-2 family. In both pathways, effector caspases are finally activated that cleave and degrade cell structures, resulting in the release of apoptotic products into the circulation. New diagnostic tests can detect these apoptotic markers and programmed cell death ligands such as Fas and Fas-ligands, nucleosomes, caspases, cytokeratin fragments, macrophage migration inhibitory factor, soluble intracellular adhesion molecule, natural killer cells group 2D and programmed death ligands. Several of these markers have been found to be altered in tissue and/or blood of immune-mediated liver diseases, some also in nonimmune-mediated liver diseases. Beyond their potential usefulness as additional diagnostic markers, they may be valuable for the estimation of disease severity and therapy monitoring. This review summarizes current knowledge on apoptotic mechanisms, death receptor ligands and circulating apoptotic markers in immune-mediated liver diseases.
DOI: 10.1586/14737159.9.2.139
PubMed: 19298138
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers.</title>
<author><name sortKey="Kremer, Andreas E" sort="Kremer, Andreas E" uniqKey="Kremer A" first="Andreas E" last="Kremer">Andreas E. Kremer</name>
<affiliation wicri:level="4"><nlm:affiliation>AMC Liver Center, S1-164, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands. a.e.kremer@amc.uva.nl</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>AMC Liver Center, S1-164, University of Amsterdam, Academic Medical Center, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
<orgName type="university">Université d'Amsterdam</orgName>
</affiliation>
</author>
<author><name sortKey="Rust, Christian" sort="Rust, Christian" uniqKey="Rust C" first="Christian" last="Rust">Christian Rust</name>
</author>
<author><name sortKey="Eichhorn, Peter" sort="Eichhorn, Peter" uniqKey="Eichhorn P" first="Peter" last="Eichhorn">Peter Eichhorn</name>
</author>
<author><name sortKey="Beuers, Ulrich" sort="Beuers, Ulrich" uniqKey="Beuers U" first="Ulrich" last="Beuers">Ulrich Beuers</name>
</author>
<author><name sortKey="Holdenrieder, Stefan" sort="Holdenrieder, Stefan" uniqKey="Holdenrieder S" first="Stefan" last="Holdenrieder">Stefan Holdenrieder</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19298138</idno>
<idno type="pmid">19298138</idno>
<idno type="doi">10.1586/14737159.9.2.139</idno>
<idno type="wicri:Area/Main/Corpus">000151</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000151</idno>
<idno type="wicri:Area/Main/Curation">000151</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000151</idno>
<idno type="wicri:Area/Main/Exploration">000151</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers.</title>
<author><name sortKey="Kremer, Andreas E" sort="Kremer, Andreas E" uniqKey="Kremer A" first="Andreas E" last="Kremer">Andreas E. Kremer</name>
<affiliation wicri:level="4"><nlm:affiliation>AMC Liver Center, S1-164, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands. a.e.kremer@amc.uva.nl</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>AMC Liver Center, S1-164, University of Amsterdam, Academic Medical Center, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
<orgName type="university">Université d'Amsterdam</orgName>
</affiliation>
</author>
<author><name sortKey="Rust, Christian" sort="Rust, Christian" uniqKey="Rust C" first="Christian" last="Rust">Christian Rust</name>
</author>
<author><name sortKey="Eichhorn, Peter" sort="Eichhorn, Peter" uniqKey="Eichhorn P" first="Peter" last="Eichhorn">Peter Eichhorn</name>
</author>
<author><name sortKey="Beuers, Ulrich" sort="Beuers, Ulrich" uniqKey="Beuers U" first="Ulrich" last="Beuers">Ulrich Beuers</name>
</author>
<author><name sortKey="Holdenrieder, Stefan" sort="Holdenrieder, Stefan" uniqKey="Holdenrieder S" first="Stefan" last="Holdenrieder">Stefan Holdenrieder</name>
</author>
</analytic>
<series><title level="j">Expert review of molecular diagnostics</title>
<idno type="eISSN">1744-8352</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apoptosis (MeSH)</term>
<term>Autoimmune Diseases (blood)</term>
<term>Autoimmune Diseases (diagnosis)</term>
<term>Autoimmune Diseases (immunology)</term>
<term>Autoimmune Diseases (therapy)</term>
<term>Biomarkers (blood)</term>
<term>Humans (MeSH)</term>
<term>Liver Diseases (blood)</term>
<term>Liver Diseases (diagnosis)</term>
<term>Liver Diseases (immunology)</term>
<term>Liver Diseases (therapy)</term>
<term>Monitoring, Physiologic (methods)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Apoptose (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Maladies auto-immunes (diagnostic)</term>
<term>Maladies auto-immunes (immunologie)</term>
<term>Maladies auto-immunes (sang)</term>
<term>Maladies auto-immunes (thérapie)</term>
<term>Maladies du foie (diagnostic)</term>
<term>Maladies du foie (immunologie)</term>
<term>Maladies du foie (sang)</term>
<term>Maladies du foie (thérapie)</term>
<term>Marqueurs biologiques (sang)</term>
<term>Monitorage physiologique (méthodes)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Autoimmune Diseases</term>
<term>Liver Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Autoimmune Diseases</term>
<term>Liver Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Maladies auto-immunes</term>
<term>Maladies du foie</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Maladies auto-immunes</term>
<term>Maladies du foie</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Autoimmune Diseases</term>
<term>Liver Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Monitoring, Physiologic</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Monitorage physiologique</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Maladies auto-immunes</term>
<term>Maladies du foie</term>
<term>Marqueurs biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Autoimmune Diseases</term>
<term>Liver Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Maladies auto-immunes</term>
<term>Maladies du foie</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Apoptosis</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Apoptose</term>
<term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis are the three major immune-mediated liver diseases. The etiologies of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis are largely unknown, but seem to be influenced by genetic and environmental factors. Autoantibodies can be found in nearly all patients with primary sclerosing cholangitis and autoimmune hepatitis, and in the vast majority of patients with primary sclerosing cholangitis. In addition, autoimmune hepatitis is associated with high concentrations of serum globulins. Enhanced liver cell death by apoptosis has been described in all of these liver diseases, although the precise mechanisms remain unclear. In general, apoptosis can be initiated via an extrinsic pathway that is triggered by engagement of death receptors on the cell surface, or via an intrinsic pathway that is induced by mitochondrial injury and is influenced by members of the Bcl-2 family. In both pathways, effector caspases are finally activated that cleave and degrade cell structures, resulting in the release of apoptotic products into the circulation. New diagnostic tests can detect these apoptotic markers and programmed cell death ligands such as Fas and Fas-ligands, nucleosomes, caspases, cytokeratin fragments, macrophage migration inhibitory factor, soluble intracellular adhesion molecule, natural killer cells group 2D and programmed death ligands. Several of these markers have been found to be altered in tissue and/or blood of immune-mediated liver diseases, some also in nonimmune-mediated liver diseases. Beyond their potential usefulness as additional diagnostic markers, they may be valuable for the estimation of disease severity and therapy monitoring. This review summarizes current knowledge on apoptotic mechanisms, death receptor ligands and circulating apoptotic markers in immune-mediated liver diseases.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19298138</PMID>
<DateCompleted><Year>2009</Year>
<Month>06</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8352</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>9</Volume>
<Issue>2</Issue>
<PubDate><Year>2009</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Expert review of molecular diagnostics</Title>
<ISOAbbreviation>Expert Rev Mol Diagn</ISOAbbreviation>
</Journal>
<ArticleTitle>Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers.</ArticleTitle>
<Pagination><MedlinePgn>139-56</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1586/14737159.9.2.139</ELocationID>
<Abstract><AbstractText>Primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis are the three major immune-mediated liver diseases. The etiologies of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis are largely unknown, but seem to be influenced by genetic and environmental factors. Autoantibodies can be found in nearly all patients with primary sclerosing cholangitis and autoimmune hepatitis, and in the vast majority of patients with primary sclerosing cholangitis. In addition, autoimmune hepatitis is associated with high concentrations of serum globulins. Enhanced liver cell death by apoptosis has been described in all of these liver diseases, although the precise mechanisms remain unclear. In general, apoptosis can be initiated via an extrinsic pathway that is triggered by engagement of death receptors on the cell surface, or via an intrinsic pathway that is induced by mitochondrial injury and is influenced by members of the Bcl-2 family. In both pathways, effector caspases are finally activated that cleave and degrade cell structures, resulting in the release of apoptotic products into the circulation. New diagnostic tests can detect these apoptotic markers and programmed cell death ligands such as Fas and Fas-ligands, nucleosomes, caspases, cytokeratin fragments, macrophage migration inhibitory factor, soluble intracellular adhesion molecule, natural killer cells group 2D and programmed death ligands. Several of these markers have been found to be altered in tissue and/or blood of immune-mediated liver diseases, some also in nonimmune-mediated liver diseases. Beyond their potential usefulness as additional diagnostic markers, they may be valuable for the estimation of disease severity and therapy monitoring. This review summarizes current knowledge on apoptotic mechanisms, death receptor ligands and circulating apoptotic markers in immune-mediated liver diseases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kremer</LastName>
<ForeName>Andreas E</ForeName>
<Initials>AE</Initials>
<AffiliationInfo><Affiliation>AMC Liver Center, S1-164, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands. a.e.kremer@amc.uva.nl</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rust</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Eichhorn</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Beuers</LastName>
<ForeName>Ulrich</ForeName>
<Initials>U</Initials>
</Author>
<Author ValidYN="Y"><LastName>Holdenrieder</LastName>
<ForeName>Stefan</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Expert Rev Mol Diagn</MedlineTA>
<NlmUniqueID>101120777</NlmUniqueID>
<ISSNLinking>1473-7159</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008107" MajorTopicYN="N">Liver Diseases</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008991" MajorTopicYN="N">Monitoring, Physiologic</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>213</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>6</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19298138</ArticleId>
<ArticleId IdType="doi">10.1586/14737159.9.2.139</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Pays-Bas</li>
</country>
<region><li>Hollande-Septentrionale</li>
</region>
<settlement><li>Amsterdam</li>
</settlement>
<orgName><li>Université d'Amsterdam</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Beuers, Ulrich" sort="Beuers, Ulrich" uniqKey="Beuers U" first="Ulrich" last="Beuers">Ulrich Beuers</name>
<name sortKey="Eichhorn, Peter" sort="Eichhorn, Peter" uniqKey="Eichhorn P" first="Peter" last="Eichhorn">Peter Eichhorn</name>
<name sortKey="Holdenrieder, Stefan" sort="Holdenrieder, Stefan" uniqKey="Holdenrieder S" first="Stefan" last="Holdenrieder">Stefan Holdenrieder</name>
<name sortKey="Rust, Christian" sort="Rust, Christian" uniqKey="Rust C" first="Christian" last="Rust">Christian Rust</name>
</noCountry>
<country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Kremer, Andreas E" sort="Kremer, Andreas E" uniqKey="Kremer A" first="Andreas E" last="Kremer">Andreas E. Kremer</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RustEffectorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000149 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000149 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Bois |area= RustEffectorV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:19298138 |texte= Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19298138" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a RustEffectorV1
![]() | This area was generated with Dilib version V0.6.37. | ![]() |